Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
June 03 2024 - 4:00AM
Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology
company focused on human diagnostics and diabetes management
solutions, including wearable biosensors, today announced the
launch of its continuous glucose monitoring (“CGM”) microsite -
https://cgm.trinitybiotech.com. This website will be used to
provide the Company’s stakeholders with key insights into the
Company’s vision for the development of the next generation of its
recently acquired CGM biosensor technology and artificial
intelligence (“AI”) driven health & wellness analytics
platform, as well as providing additional visibility on the
international commercialisation of these solutions.
Trinity Biotech President and Chief Executive Officer, Mr John
Gillard stated, “We continue to make significant progress to
advance the development of our next generation CGM and AI driven
health and wellness analytics technology towards launches across
global markets. To increase the understanding and visibility of
this technology, and its benefits, we have launched
https://cgm.trinitybiotech.com, a dedicated website for key
stakeholders, including potential users, payers and physicians,
which provides insights on the design philosophy underpinning our
vision for this technology. Our design and development rationale is
built around the key factors of usability, affordability and
sustainability. We believe that these are fundamental factors
in facilitating accessibility to this critically important
technology globally, where there continues to be a very large unmet
need amongst those hundreds of millions of people globally who are
impacted by diabetes. We encourage all interested parties to
sign up to receive our newsletter and email alerts on our
progress.”
Forward-Looking Statements
This release includes statements that constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (the “Reform Act”),
including but not limited to statements related to Trinity
Biotech’s cash position, financial resources and potential for
future growth, market acceptance and penetration of new or planned
product offerings, and future recurring revenues and results of
operations. Trinity Biotech claims the protection of the
safe-harbor for forward-looking statements contained in the Reform
Act. These forward-looking statements are often characterised by
the terms “may,” “believes,” “projects,” “expects,” “anticipates,”
or words of similar import, and do not reflect historical facts.
Specific forward-looking statements contained in this presentation
may be affected by risks and uncertainties, including, but not
limited to, our ability to capitalize on our purchase of the assets
of Waveform, our continued listing on the Nasdaq Stock Market, our
ability to achieve profitable operations in the future, the
impact of the spread of COVID-19 and its variants, potential excess
inventory levels and inventory imbalances at the company’s
distributors, losses or system failures with respect to Trinity
Biotech’s facilities or manufacturing operations, the effect of
exchange rate fluctuations on international operations,
fluctuations in quarterly operating results, dependence on
suppliers, the market acceptance of Trinity Biotech’s products and
services, the continuing development of its products, required
government approvals, risks associated with manufacturing and
distributing its products on a commercial scale free of defects,
risks related to the introduction of new instruments manufactured
by third parties, risks associated with competing in the human
diagnostic market, risks related to the protection of Trinity
Biotech’s intellectual property or claims of infringement of
intellectual property asserted by third parties and risks related
to condition of the United States economy and other risks detailed
under “Risk Factors” in Trinity Biotech’s annual report on Form
20-F for the fiscal year ended December 31, 2023 and Trinity
Biotech’s other periodic reports filed from time to time with the
United States Securities and Exchange Commission. Forward-looking
statements speak only as of the date the statements were made.
Trinity Biotech does not undertake and specifically disclaims any
obligation to update any forward-looking statements.
About Trinity BiotechTrinity
Biotech is a commercial stage biotechnology company focused on
human diagnostics and diabetes management solutions, including
wearable biosensors. The Company develops, acquires,
manufactures and markets diagnostic systems, including both
reagents and instrumentation, for the point-of-care and clinical
laboratory segments of the diagnostic market and has recently
entered the wearable biosensor industry, with the acquisition of
the biosensor assets of Waveform Technologies Inc. and intends to
develop a range of biosensor devices and related services, starting
with a continuous glucose monitoring product. The products are used
to detect infectious diseases and to quantify the level of
Haemoglobin A1c and other chemistry parameters in serum, plasma and
whole blood. Trinity Biotech sells direct in the United States,
Germany, France and the U.K. and through a network of international
distributors and strategic partners in over 75 countries worldwide.
For further information, please see the Company's website:
www.trinitybiotech.com.
Contact: |
Trinity Biotech plc |
LifeSci Partners, LLC |
|
Gary Keating, Ph.D. |
Eric Ribner |
|
(353)-1-2769800 |
(1)-646-751-4363 |
|
|
E-mail:investorrelations@trinitybiotech.com |
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Jul 2024 to Aug 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Aug 2023 to Aug 2024